All Online

1 - 5 of 5 results


Active filters

Screening for HIV

This case-based, interactive lecture will cover the current epidemiology of HIV in the United States, and then focus on issues critical for the primary care provider - HIV testing, identification of acute infection, initiating a baseline work-up, and understanding the basics of antiretroviral therapy. HIV prevention will be covered citing both the pre- and post-exposure prophylaxis strategies.

This talk will review the latest epidemiology of the HIV epidemic in New York. The 2015 update of the Department of Health and Human Services guidelines for first-line treatment regimens will be discussed, and a brief update of the latest data on treatment as prevention will be presented. The latest data addressing the advantages of the early initiation of antiretrovirals will also be presented. Finally, Dr. Scherer will discuss pre-exposure prophylaxis, or PrEP, and will provide practical guidance for the provision of PrEP in primary care practice.


The USPSTF recently issued a Draft Grade A recommendation that all at-risk patients be offered pre-exposure prophylaxis to prevent the transmission of HIV. This multi drug, single pill regimen can lower risk of HIV and potentially prevent lifelong burden of disease. While only a draft recommendation, the USPSTF expects, after stakeholder comment, to continue to support an A recommendation to offer for all patients who are increased risk.


In the Unites States, it is estimated that there are 1.2 million persons living with HIV. This program will discuss appropriate screening patients for HIV infection and how to recognize signs and symptoms of acute retroviral syndrome. Treatment will also be discussed along with what factors influence the selection of an antiretroviral regimen and when pre-exposure prophylaxis is indicated. 


This talk will review the current data to support the use of pre-exposure prophylaxis for HIV infection. You will learn about clinical implementation of PrEP in practice and discuss challenging case scenarios. Future directions for PrEP and novel agents in development will be briefly presented.